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Abstract
Tubular cell HIV-infection has been reported to manifest in the form of cellular hypertrophy and apoptosis. In the present
study, we evaluated the role of mammalian target of rapamycin (mTOR) pathway in the HIV induction of tubular cell protein
synthesis. Mouse proximal tubular epithelial cells (MPTECs) were transduced with either gag/pol-deleted NL4-3 (HIV/MPTEC)
or empty vector (Vector/MPTEC). HIV/MPTEC showed enhanced DNA synthesis when compared with Vector/MPTECs by
BRDU labeling studies. HIV/MPTECs also showed enhanced production of b-laminin and fibronection in addition to
increased protein content per cell. In in vivo studies, renal cortical sections from HIV transgenic mice and HIVAN patients
showed enhanced tubular cell phosphorylation of mTOR. Analysis of mTOR revealed increased expression of phospho (p)-
mTOR in HIV/MPTECs when compared to vector/MPTECs. Further downstream analysis of mTOR pathway revealed
enhanced phosphorylation of p70S6 kinase and associated diminished phosphorylation of eEF2 (eukaryotic translation
elongation factor 2) in HIV/MPTECs; moreover, HIV/MPTECs displayed enhanced phosphorylation of eIF4B (eukaryotic
translation initiation factor 4B) and 4EBP-1 (eukaryotic 4E binding protein). To confirm our hypothesis, we evaluated the
effect of rapamycin on HIV-induced tubular cell downstream signaling. Rapamycin not only attenuated phosphorylation of
p70S6 kinase and associated down stream signaling in HIV/MPTECs but also inhibited HIV-1 induced tubular cell protein
synthesis. These findings suggest that mTOR pathway is activated in HIV-induced enhanced tubular cell protein synthesis
and contributes to tubular cell hypertrophy.
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Introduction
HIV-associated nephropathy (HIVAN) is characterized by
tubular microcyst formation [1]. Tubular cells in these lesions
display growth arrest, hypetrophy and apoptosis [2]. The role of
mTOR in the development of cysts both in animal and human
models of polycystic disease has been reported [3–6]. Recently,
the role of mTOR has been suggested in the development of
renal lesions in a mouse model of HIVAN [7]. In these studies,
HIV transgenic mice (Tg26) displayed expression of phospho-
mTOR by kidney cells. Renal tissues from Tg26 mice not only
displayed enhanced phosphorylation of p70S6 kinase and
eEF2K but also showed enhanced phosphorylation of 4E-BP-1
and eIF4B; these findings indicated the activation of mTOR
pathway in kidney cells of HIV transgenic mice. However,
whether mTOR activation contributes to the induction of
tubular cell protein synthesis was not evaluated in those studies.
Recent investigations have revealed that mTOR activation
occurs in two distinct complexes: the mTOR complex1
(mTORC1) made up of mTOR, raptor, mSLT8, and,
mTORC2 consisting of mTOR, rictor, diptor and mSLT8 [8].
Since mTORC1 plays an important role in the regulation of
mRNA translation, a rate-limiting step in protein synthesis, we
hypothesized that HIV-1 recruits mTOR for the induction of
tubular cell protein synthesis.
mTORC1 is an important regulator of mRNA translation by
two distinct but integrated pathways [8-10]. One track leads to the
phosphorylation of ribosomal protein S6 by the ribosomal S6
kinase that stimulates the translation of mRNAs, which encode
many components of the protein synthetic machinery- ribosomal
proteins and translation initiation and elongation factors associ-
ated with regulating protein synthesis rates [9,10]. The second
track of the mTORC1-dependent pathway controls phosphoryla-
tion of 4EBP1 by releasing its inhibitory interaction with eIF4E,
and thus allowing eIF4E to associate with eIF4G; the latter forms
the active eIF4F complex that binds to the 59 cap of the mRNA
and facilitates the initiation phase of mRNA translation. eIF4E
activity is important for the translation of transcripts of mRNAs
encoding many proteins associated with growth and proliferation
control such as cyclin D1 and c-myc [9,10]. In mammalian cells,
both 4EBP1/eIF4E and S6K are necessary for effective regulation
of cell mass [9,10].
In the recent years, activation of mTORC1 pathway has been
shown in renal diseases in experimental animals and humans [11–
15]. On that account, rapamycin, an inhibitor of mTOR pathway,
has been used to attenuate s inflammation associated with allograft
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membranous nephropathy, diabetic nephropathy, Thy 1.1
nephritis, and polycystic kidney disease in animal experimental
models [11–14]. Recently, HIV transgenic mice-receiving rapa-
mycin displayed attenuated renal lesions, proteinuria and uremia
[7]. Moreover, in these studies renal tissues of HIVAN mice
showed inhibition of the mTOR-associated downstream signaling.
Thus, it appears that modulation of mTOR can be used as an
effective therapeutic tool to provide protection against the
progression of renal diseases in patients with HIVAN.
In the present study, we examined the effect of HIV-1 infection
on the activation of mTORC1 pathway in mouse tubular cells and
its outcome on tubular cell growth. In addition, we studied the
effect of rapamycin, an inhibitor of mTORC1, on HIV-1-induced
tubular cell mTORC1 pathway activation and associated effects
on tubular cell protein synthesis and its protein content.
Materials and Methods
HIV transgenic mice (Tg26)
We used age and sex matched FVB/N (control) and Tg26 (on
FVB/N background). Breeding pairs of FVBN were obtained from
Jackson Laboratories (Bar Harbor, ME). Breeding pairs to develop
Tg26 colonies were kindly gifted by Prof. Paul E. Klotman M.D.,
President and CEO, Baylor Medical College, Houston, TX). The
Tg26 transgenic animal has the proviral transgene, pNL4-3:
d1443, which encodes all the HIV-1 genes except gag and pol;
therefore, the mice are noninfectious. Mice were housed in groups
of 4 in a laminar-flow facility (Small Animal Facility, Long Island
Jewish Medical Center, New Hyde Park, NY). We breed and
maintain colonies of these animals in our animal facility.
Human renal biopsy specimens
Archived renal biopsy specimens from patients with idiopathic
focal glomerulosclerosis and HIVAN were obtained from the
Pathology Department at our institution. Protocol for use of
human tissue was approved by the Institutional Review Board of
Feinstein Institute for Medical Research, Manhasset, NY.
Proximal tubular cells
Mouse proximal tubular epithelial cells (MTC) were gift from
Dr. G. Wolf (Department of Medicine, Hamburg, Germany).
These cells are well characterized and expressed tubular cell
markers [16].
Production of Pseudotyped Retroviral Supernatant
Replication defective viral supernatants were prepared as
published previously [17]. In brief, green fluorescence protein
(GFP) reporter gene (from pEGFP-C1; Clontech, Palo Alto, CA)
was substituted in place of gag/pol genes in HIV-1 proviral
construct pNL4–3. This parental construct (pNL4-3: DG/P-GFP)
was used to produce VSV.G pseudotyped viruses to provide
pleiotropism and high-titer virus stocks. Infectious viral superna-
tants were produced by transient transfection of 293T cells using
Effectene (Qiagen Inc.) according to the manufacturer’s instruc-
tions. The HIV-1 gag/pol and VSV.G envelope genes were
provided in trans using pCMV R8.91 and pMD.G plasmids,
respectively (gifts of Dr. Didier Trono, Salk Institute, La Jolla,
CA). As a negative control, virus was also produced from pHR-
CMV-IRES2-GFP-DB, which contained HIV-1 LTRs and GFP
empty expression vector. The viral stocks were titrated by infecting
293T cells with ten-fold serial dilution as reported previously [17].
The reciprocal of the lowest dilution showing the expression of
GFP was defined as GFP-expressing units (GEU) per ml. Viral
stocks ranging from 10
6 to 10
8 GEU/ml were obtained. Low-titer
viral stocks were further concentrated by high speed centrifuga-
tion.
Determination of cellular protein content
Equal numbers of MPTECs were transduced with empty vector
or NL4-3 and then incubated in media for 72 hours. At the end of
the incubation period, cells were harvested and counted by a
hemocytometer. Protein was extracted, measured, and, protein
content was calculated per cell.
Determination of DNA synthesis
Equal numbers of EV/MPTECs and NL4-3/MPTECs were
seeded in 96-well plates. Cells were labeled for 12 hours and
analyzed as per manufacturer instruction (Calbiochem, La Jolla,
CA).
Immunohistochemical staining
The immunohistochemistry protocol used in the present study
has been described previously [7]. The primary antibody-
phospho-mTOR (1:500, #2971, Cell Signaling Technology Inc.,
Danvers, MA)- was followed by the secondary antibody at 1:250
dilution and then incubated in ABC reagent (Vector Laboratories,
Burlingame, CA) for 30 minutes. Sections were washed thrice in
PBS and placed in VECTOR Nova RED substrate kit SK-4800
(Vector Laboratories, Burlingame, CA) followed by counterstain-
ing with methyl green.
Western blotting studies
NL4-3/MPTECs and EV/MPTECs under control and
experimental conditions were incubated in media for 72 hours.
At the end of the incubation period, cells were harvested, lysed in
RIPA buffer containing 50 mM Tris-Cl (pH 7.5), 150 mM NaCl,
1mM EDTA, 1% NP-40, 0.25% Deoxycholate, 0.1% SDS, 1X
protease inhibitor cocktail (Calbiochem, Cocktail Set I), 1mM
PMSF, and 0.2mM sodium orthovanadate. Protein concentration
was measured by Bradford Assay (Bio-Rad , Hercules, CA). Total
protein extracts (2 mg/ml) were separated on a 4-15% poly-
acrylamide (PAGE) gel and transferred onto a nitrocellulose
membrane using Bio-Rad miniblot apparatus. The blots were
blocked with 5% milk and 0.1% TWEEN 20 in 1X PBS for
60 min at room temperature and then hybridized with the
antiphospho-mTOR (1:500, Cell Signaling Technology Inc.,
Danvers, MA), antiphospho-p70S6K (1:500, Abcam, Cambridge,
MA), antiphospho-eEF2 (1:500, rabbit polyclonal, Cell Signaling,
antiphospho-4EBP1 (1:500, rabbit polyclonal, Cell Signaling),
phospho-eIF4B (1:500, rabbit polyclonal, Cell Signaling), and
antiphospho-UBF (1:500, SantaCruz Biotechnology, Santa Cruz,
CA) antibodies and subsequently treated with horseradish
peroxidase labeled appropriate secondary antibodies. The blots
were developed using a chemiluminescence detection kit
(PIERCE, Rockford, IL) and exposed to X-ray film (Eastman
Kodak Co., Rochester, NY). Equal protein loading and the
protein transfer were confirmed by stripping and immunoblotting
for actin protein using a polyclonal a-Actin antibody (I-19,
SantaCruz) on the same Western blots.
Statistical analysis
For comparison of mean values between two groups, the
unpaired t test was used. To compare values between multiple
groups, analysis of variance (ANOVA) was applied and a
Bonferroni multiple range test was used to calculate a p-value.
Statistical significance was defined as P,0.05.
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Tubular cells show enhanced tubular cell mTOR
phosphorlyation in HIVAN Patients and HIVTg mice
Renal cortical sections of human biopsy specimens and HIVAN
mice were immunolabeled for phospho-mTOR and evaluated for
tubular cell expression of phospho-mTOR. As shown in Fig. 1,
dilated tubules in both HIVAN patients and Tg26 mice displayed
enhanced phospho-mTOR expression by tubular cells. These
findings indicate the activation of mTOR pathway in diseased
tubules in HIVAN patients and Tg26 mice.
HIV promotes mTOR pathway activation in Tubular cells
To determine the activation of mTOR pathway, lysates from
vector/MPTECs and HIV/MPTECs were prepared for West-
ern blotting and probed for the expression of proteins molecules
involved in the downstream signaling of the mTORC1 pathway
(n=4). Representative gels (in duplicate) are shown in Fig. 2.
Immunoblots of HIV/MPTECs showed increase in phos
(Ser
2448)o fm T O Ra n di np h o s( T h r
389)o fp 7 0 S 6k i n a s e ,
demonstrating the activation of mTORC1 in HIV/MPTECs.
Moreover, reduction in eEF2 phos (Thr
56) is indicative of
increase in p70S6 kinase activation and stimulation of
elongation phase of mRNA translation in proximal tubular
epithelial cells [18]. Cumulative data (n=4) are represented by
bar graphs. Similarly, enhanced phosphorylation of 4EBP1 and
eIF4B in HIV/MPTECs (Fig. 3) indicates activation of the
initiation phase of mRNA translation and further confirms the
activation of the mTORC1 pathway in HIV/MPTECs.
Cumulative data (n=4) are represented by bar graphs. Thus,
HIV/MPTECs display evidence of mTOR activation and the
stimulation of both initiation and elongation phases of mRNA
translation.
HIV/MPTECs display enhanced phosphorylation of UBF
(upstream binding factor)
Regulation of mRNA translation can occur at the level of
efficiency and/or capacity. The latter depends on the generation
of more ribosomes, which would ultimately permit the cell to
rapidly ramp up protein synthesis [19]. Since stimulation of
ribosomal DNA (rDNA) transcription by mTOR is mediated in
part through the phosphorylation of the carboxy-terminal
activation domain of the rDNA transcription factor, upstream
binding factor (UBF) [20], we also evaluated the effect of HIV
infection on phospho-UBF expression by tubular cells. Lysates
were prepared from vector/MPTECs and HIV/MPTECs and
proteins were probed for phospho-UBF and total UBF. As shown
in Fig. 4A, HIV/MPTECs displayed enhanced expression of
phospho-UBF. These findings indicate that HIV may be
stimulating rDNA transcription and ribosomal biogenesis in
tubular cells through the activation of UBF.
HIV enhances tubular cell DNA synthesis and increases
intracellular protein content
Since mTORC1 pathway enhances protein synthesis, we
determined whether the activation of HIV-induced mTOR
pathway is associated with enhanced protein synthesis in MPTECs.
Control and HIV/MPTECs were pulsed with BRDU and BRDU
incorporation was assayed by ELISA. As shown in Fig. 4B, HIV/
MPTECs displayed increased (P,0.02) BRDU labeling (DNA
synthesis). In addition, vector/MPTECs and HIV/MPTECs were
growth arrested and then stimulated to grow for 48 hours.
Intracellular protein content was calculated by measuring total
numberofcellsand totalamount ofproteininvector/MPTECs and
HIV/MPTECs. As shown in Fig. 4C, HIV/MPTECs displayed
increased (P,0.01) protein content per cell (n=3). These data show
that HIV promoted hypertrophy of tubular cells.
Figure 1. Tubular cells display enhanced phosphorlyation of mTOR in HIVAN. Renal biopsy specimens from patients with idiopathic focal
and segmental glomerulosclerosis and HIVAN were immunolabeled for phospho-mTOR. Representative microphotograph from a patient with focal
glomerulosclerosis (A) and a HIVAN patient (B) are shown. Renal tubular cells in dilated tubules displayed phosphorylation of mTOR (brown staining,
indicated by arrows). Renal cortical sections of control (n=3) and HIVAN (n=3) mice were immunolabeled for phospho-mTOR and evaluated for
tubular cell expression of phospho-mTOR. Representative microphotographs of a control (C) and HIVAN (D) mice are shown. Tubular cells in dilated
tubules displayed enhanced phosphorylation of mTOR (brown staining, indicated by arrows).
doi:10.1371/journal.pone.0030071.g001
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vector or NL4-3 and then incubated in media for 72 hours. Subsequently, proteins were extracted from vector/MPTECs and HIV/MPTECs, Western
blots were prepared and probed for phospho-mTOR, p70S6K, and phospho-eEF2. Immunoblots were stripped and reprobed either for total mTOR or
actin (n=4). A. Representative gels (in duplicate) showing tubular cell expression of phospho-mTOR under control (vector) and HIV infection states
(upper lane). The lower lane shows tubular cell expression of total mTOR under similar conditions. A bar diagram showing cumulative data of 4 sets of
experiments is shown in the right panel. B. Representative gels (in duplicate) showing tubular cell expression of phospho-p70S6K under control
(vector) and HIV infection states (upper lane). The lower lane shows tubular cell expression of actin under similar conditions. A bar diagram showing
cumulative data of 4 sets of experiments is shown in the right panel. C. Representative gels (in duplicate) showing tubular cell expression of phospho-
eEF2 under control (vector) and HIV infection states (upper lane). The lower lane shows tubular cell expression of actin under similar conditions. A bar
diagram showing cumulative data of 4 sets of experiments is shown in the right panel.
doi:10.1371/journal.pone.0030071.g002
Figure 3. HIV induces phosphorylation p70S6K and downstream signaling in Tubular cells. MPTECs were tranduced either with empty
vector or NL4-3 and then incubated in media for 72 hours. Subsequently, proteins were extracted from vector/MPTECs and HIV/MPTECs, Western
blots were prepared and probed for phospho-70S6K, phospho-eIF4B, and phospho-4EBP1. Immunoblots were stripped and reprobed for actin (n=4).
A. Representative gels (in duplicate) showing tubular cell expression of phospho-70S6K under control (vector) and HIV infection states (upper lane).
The lower lane shows tubular cell expression of actin under similar conditions. A bar diagram shows cumulative data of four sets of experiments in
the right panel. B. Representative gels (in duplicate) showing tubular cell expression of phospho-eIF4B under control (vector) and HIV infection states
(upper lane). The lower lane shows tubular cell expression of actin under similar conditions. A bar diagram showing cumulative data of four sets of
experiments is in the right panel. C. Representative gels (in duplicate) showing tubular cell expression of phospho-EBP1 under control (vector) and
HIV infection states (upper lane). The lower lane shows tubular cell expression of actin under similar conditions. A bar diagram showing cumulative
data of 4 sets of experiments is shown in the right panel.
doi:10.1371/journal.pone.0030071.g003
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pathway signaling
To determine the effect of rapamycin on HIV-induced tubular
cell mTOR phosphorylation, proteins were extracted from vector/
MPTECs and HIV/MPTECs, and HIV + R/MPTECs and
protein lysates probed for the expression of phospho-mTOR and
total mTOR. Representative gels (in duplicate) are shown in
Fig. 5A. Cumulative data (n=4) are shown in the form of
graphical representation. HIV/MPTECs displayed enhanced
(P,0.01) mTOR phosphorylation; however, rapamycin inhibited
(P,0.01) this effect of HIV on tubular cells.
Immunoblots prepared under above mentioned conditions
were probed for the expression of phospho-p70S6K and actin.
Representative gels (in duplicate) are shown in Fig. 5B.
Cumulative data (n=4) are represented by a bar diagram.
HIV/MPTECs displayed enhanced (P,0.01) expression of
phos-p70S6K that was completely inhibited by rapamycin
(P,0.01).
Similarly, immunoblots were probed for the expression of
phospho-eEF2 and actin. Representative gels (in duplicate) are
shown in Fig. 6. Cumulative data (n=4) are shown as bar graphs.
HIV/MPTECs displayed diminished (P,0.01) expression of
phospho-eEF2 that was restored by rapamycin (P,0.01).
Immunoblots were also probed for the expression of phospho-
eIF4B and actin. eIF4B is believed to assist the helicase action of
eIF4A during the initiation phase of translation; it is activated by
phosphorylation by p70S6 kinase [21], which, in turn, is
dependent on mTORC1. Representative gels (in duplicate) are
shown in Fig. 7A. Cumulative data (n=4) in the form of a bar
diagram is also shown. HIV/MPTECs displayed enhanced
(P,0.01) expression of phos-eIF4B; again, this was neutralized
by rapamycin (P,0.01). Similar effect of rapamycin was seen in
Figure 4. HIV enhances tubular cell UBF phosphorylation, DNA
synthesis and intracellular protein content. A. Vector/MPTECs and
HIV/MPTECs were incubated in media for 72 hours. Subsequently,
proteins were extracted and probed for phospho-UBF and total UBF.
Representative gels (in duplicate) are shown displaying tubular cell
expression of phospho-UBF and toral UBF. The upper lane shows the
effect of HIV on tubular cell expression of phospho-UBF. The lower lane
shows lane total tubular cell UBF expression under similar conditions. B.
Vector/MPTECs (control) and HIV/MPTECs were incubated 96 well plates
and pulsed with BRDU and incubated for 72 hours. BRDU incorporation
in MPTECs was assayed by ELISA. Cumulative data of three sets of
experiments is show in the form a bar diagrams C. Vector/MPTECs and
HIV/MPTECs were growth arrested and then incubated in media
containing 1% serum for 72 hours. At the end of the incubation period,
cells were harvested, total number of cells were counted and proteins
were extracted. Protein content per cell was calculated. Cumulative
data are displayed as bar graphs.
doi:10.1371/journal.pone.0030071.g004
Figure 5. Rapamycin inhibits HIV-induced tubular cell phos-
phorylation of mTOR and 70S6K. A. MPTECs were transduced
either empty vector (Vector), NL4-3 (HIV) and incubated in media
containing either buffer or rapamycin (100 nM) for 72 hours.
Subsequently, proteins were extracted, Western blots were prepared
and probed for phospho-mTOR. The blots were stripped and reprobed
for total mTOR. Representative gels (in duplicate) showing tubular cell
phospho-mTOR in control (vector), HIV infected (HIV) and rapamycin-
treated/HIV-infected (HIV + R) cells are shown (upper lane). The lower
lane shows tubular cell expression of mTOR under similar conditions.
Cumulative data of four sets of experiments in the form of a bar
diagram are displayed in the lower panel. P,0.01 compared to vector
and HIV + R. B. Proteins from the MPTECs treated under similar
condition were probed for phospho-70S6K. The blots were stripped and
reprobed for actin. Representative gels (in duplicate) showing tubular
cell phospho-70S6K in control (vector), HIV infected (HIV) and
rapamycin-treated/HIV-infected (HIV + R) cells are shown (upper lane).
The lower lane shows tubular cell expression of actin under similar
conditions. Cumulative data of four sets of experiments in the form of a
bar diagram are displayed in the lower panel. *P,0.01 compared to
vector and HIV + R.
doi:10.1371/journal.pone.0030071.g005
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p,0.01).
Rapamycin inhibits HIV-induced tubular cell b-laminin
and fibronectin synthesis
Activation of mTOR pathway enhances the synthesis of several
matrix proteins amongst them b-laminin1 and fibronectin are
main targets. To evaluate the effect of rapamycin on HIV-induced
tubular cell b-laminin synthesis, proteins were extracted from
vector/MPTECs, HIV/MPTECs, and HIV + R/MPTECs.
Western blots were probed for b-laminin1 and actin. Represen-
tative gels (in duplicate) are shown in Fig. 8A. Cumulative data
(n=4) are shown as bar diagrams. HIV/MPTECs displayed
enhanced (P,0.01) expression of b-laminin1; rapamycin inhibited
(P,0.01) the HIV-induced increment.
Similarly, analysis of fibronectin through Western blots revealed
enhanced fibronectin synthesis in tubular cells exposed to HIV
that was completely abolished by rapamycin (Fig. 8B, p,0.01).
Rapamycin inhibits HIV-induced tubular cell protein
synthesis
To determine the effect of mTOR pathway inhibition on HIV-
induced tubular cell protein synthesis, vector/MPTECs, HIV/
MPTECs, and HIV + R/MPTECs were growth arrested and then
allowed to grow for 48 hours. Intracellular protein content per cell
was calculated by measuring total number of cells and total
amount of protein. As shown in Fig. 9, HIV/MPTECs displayed
increased (P,0.05) protein content per cell. However, rapamycin
inhibited (P,0.05) this effect of HIV on tubular cell protein
synthesis.
Discussion
In the present study, HIV/MPTECs showed occurrence of
enhanced DNA synthesis in the form of increased BRDU labeling.
In addition, HIV/MPTECs showed enhanced expression of b-
laminin, fibronectin, and increased amount of protein content per
cell. Immunoblot data of HIV/MPTECs showed enhanced in
phos (Ser
2448) of mTOR and in phos (Thr
389) of p70S6 kinase;
these findings indicated the activation of mTORC1 pathway in
HIV-1-infected tubular cells. Similarly, a reduction in eEF2 phos
on Thr
56 also indicated the activation of p70S6 kinase and
stimulation of elongation phase of mRNA translation in HIV-1-
infected tubular cells. Enhanced phosphorylation of 4EBP1 and
eIF4B in HIV/MPTECs strongly suggests stimulation of the
initiation of mRNA translation phase. These findings indicated the
activation of mTORC1 pathway in HIV-infected tubular cells.
However, immunoblot analyses of data from rapamycin-treated
HIV/MPTEC demonstrated attenuated phos (Thr
389) of p70S6K
thus, suggesting inhibition of mTORC1. Further, protein
expression of rapamycin treated HIV/MPTEC showed an
increase in eEF2 phos of Thr
56 (when compared to HIV/
MPTECs), which is indicative of inhibition of p70S6 kinase and
associated inhibition of the elongation phase of mRNA translation.
Rapamycin treated HIV/MPTECs not only attenuated expression
of b-laminin and fibronectin but also displayed attenuated protein
content when compared to HIV/MPTECs.
Figure 6. Rapamycin inhibits HIV-induced tubular cell phos-
phorylation of eEF2. MPTECs were transduced either empty vector
(Vector), NL4-3 (HIV) and incubated in media containing either buffer or
rapamycin (100 nM) for 72 hours. Subsequently, proteins were
extracted, Western blots were prepared and probed for phospho-
eEF2. Immunoblots were stripped and reprobed for actin mTOR.
Representative gels (in duplicate) showing tubular cell phospho-eEF2 in
control (vector), HIV infected (HIV) and rapamycin-treated/HIV-infected
(HIV + R) cells are shown (upper lane). The lower lane shows tubular cell
expression of actin under similar conditions. Cumulative data of four
sets of experiments in the form of a bar diagram are displayed in the
lower panel. *P,0.01 compared to vector and HIV + R.
doi:10.1371/journal.pone.0030071.g006
Figure 7. Rapamycin inhibits HIV-induced tubular cell phos-
phorylation of eIF4B and EBP1. A. MPTECs were transduced either
empty vector (Vector), NL4-3 (HIV) and incubated in media containing
either buffer or rapamycin (100 nM) for 72 hours. Subsequently,
proteins were extracted, Western blots were prepared and probed for
phospho-eIF4B. Immunoblots were stripped and reprobed for actin.
Representative gels (in duplicate) showing tubular cell phospho-eIF4B
in control (vector), HIV infected (HIV) and rapamycin-treated/HIV-
infected (HIV + R) cells are shown (upper lane). The lower lane shows
tubular cell expression of actin under similar conditions. Cumulative
data of four sets of experiments in the form of a bar diagram are
displayed in the lower panel. *P,0.01 compared to vector and HIV + R.
B. Proteins from the MPTECs treated under similar conditions were
probed for phospho-4EBP1. The blots were stripped and reprobed for
actin. Representative gels (in duplicate) showing tubular cell phos-
pho4EBP1 in control (vector), HIV infected (HIV) and rapamycin-treated/
HIV-infected (HIV + R) cells are shown (upper lane). The lower lane
shows tubular cell expression of actin under similar conditions.
Cumulative data of four sets of experiments in the form of a bar
diagram are displayed in the lower panel. *P,0.001 compared to
vector. **P,0.01 compared to HIV + R.
doi:10.1371/journal.pone.0030071.g007
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contribute to the pathogenesis of cystic kidney diseases [3,4].
Induction of phospho-mTOR and p70S6K has been demonstrated
in cyst-lining epithelial cells in cysts both from mouse and human
kidneys [4]. Han:SPRD/PKD rat kidneys showed enhanced
expression of p70S6K (Thr
389) and total S6K and thus indicating
the activation of the mTOR pathway [3]; moreover, rapamycin
inhibited the activation of the mTOR pathway in kidneys of
Han:SPRD rats. In the present study, we observed enhanced
tubularcell phosphorylationofmTOR indilatedtubulesofHIVAN
patients as well HIVAN mice. These findings areconsistent with the
observations of other investigators indicating the activation of the
mTOR pathway in epithelial lining of cystic tubules.
The mTOR pathway responds to growth factors and mitogens
and stimulates cap-dependent translation, whereas amino-acid
deprivation and hypoxic stress down regulate this pathway and
thus leading to a reduction in global protein synthesis [22–26].
Interestingly, in the present study, HIV hijacked kidney cell genome
to activate mTOR pathway to enhance protein translation needed
for viral replication. The mTOR exists in two complexes:
mTORC1, which is rapamycin-sensitive and promotes downstream
signaling through the phosphorylation of p70S6K and eukaryotic
initiation factor 4E binding proteins (4EBPs), whereas, mTORC2 is
rapamycin-insensitive and phosphorylates AKT [18]. Although
both mTOR complexes are stimulated by mitogens, but only
mTORC1 is under the control of nutrient and energy inputs. Down
regulation of mTOR pathway is associated with resistance to
oxidative, osmotic, hypoxic and apoptotic stresses [22–26]. On the
other hand, over-activation of the mTOR pathway leads to higher
than normal protein synthesis in several disease states. Increase in
phosphorylation of Thr389 on p70S6 kinase and Thr37/46 on 4E-
BP1 are indices of activation of mTORC1. This was further
supported by the ability of rapamycin to inhibit these events in
addition to general protein synthesis induced by HIV.
Loss of critical neprhon mass was demonstrated to be associated
with progressive renal failure both in animal and human disease
models of kidney diseases (27]. Initially, the loss of nephrons was
associated with compensatory renal hypertrophy [27–29]. The
mTOR was implicated as the major pathway which contributed to
renal hypertrophy [30]. Activation of the mTOR pathway was
displayed in the form of enhanced renal tissue phosphorylation of
p70S6K and 4EBP1 in the remaining kidney in a uni-
nephrectomy model [30]; conversely, inhibition of the mTOR
pathway by rapamycin in this model was associated with
attenuation of renal hypertrophy [30]. Moreover, in mice with
genetically engineered deletion of p70S6 kinase, renal hypertrophy
was not seen either with diabetes or following uninephrectomy
[31]. Interestingly, rapamycin inhibited tubular dilatation and
interstitial volume in a unilateral ureteral obstruction (UUO)
mouse model [32]. In the latter model, rapamycin not only
diminished the infiltration of inflammatory cells but also
attenuated renal tissue transforming growth factor-b1 expression.
The authors suggested the role the mTORC1 pathway activation
in the progression of tubulo-interstitial injury and fibrosis in
obstructive uropathy [32]. Similarly, rapamycin not only inhibited
mTOR-induced downstream signaling but also attenuated the
progression of tubular lesions in a mouse model of HIVAN [7]. In
the present study, rapamycin attenuated the HIV-1- induced
tubular cell activation of the mTORC1 pathway as well as tubular
cell protein synthesis; these findings provide evidence that
mTORC1 contributes to tubular cell hypertrophy during HIV
infection.
Figure 8. Rapamycin inhibits HIV-induced tubular cell b-
laminin and fibronectin synthesis. A. MPTECs were transduced
either empty vector (Vector), NL4-3 (HIV) and incubated in media
containing either buffer or rapamycin (100 nM) for 48 hours.
Subsequently, proteins were extracted, Western blots were probed
for b-laminin1. Immunoblots were stripped and reprobed for actin.
Representative gels (in duplicate) showing tubular cell b-laminin1 in
control (vector), HIV infected (HIV) and rapamycin-treated/HIV-infected
(HIV + R) cells are shown (upper lane). The lower lane shows tubular cell
expression of actin under similar conditions. Cumulative data of four
sets of experiments in the form of a bar diagram are displayed in the
lower panel. *P,0.01 compared to vector and HIV + R. B. Proteins from
the MPTECs treated under similar conditions were probed for
fibronectin. The blots were stripped and reprobed for actin. Represen-
tative gels (in duplicate) showing tubular cell fibronectin in control
(vector), HIV infected (HIV) and rapamycin-treated/HIV-infected (HIV +
R) cells are shown (upper lane). The lower lane shows tubular cell
expression of actin under similar conditions. Cumulative data of four
sets of experiments in the form of a bar diagram are displayed in the
lower panel. *P,0.001 compared to vector and HIV + R.
doi:10.1371/journal.pone.0030071.g008
Figure 9. Effect of rapamycin on HIV-induced tubular cell
protein synthesis. Growth arrested vector/MPTECs, and HIV/MPTECs
with or without rapamycin (100 nM) were incubated in media for
48 hours. Subsequently, number of cells were counted and total
proteins were measured quantitatively. Protein content per cell was
calculated (n=3). P,0.05 compared to vector and HIV + R.
doi:10.1371/journal.pone.0030071.g009
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outcome in terms of enhanced protein synthesis may be
completely different. For example, the activation of the mTOR
pathway has been shown to occur in both human and mouse lupus
nephritis [33], and anti-Thy1.1-induced chronic glomerulosclero-
sis in the rat [34,35], but these nephritic lesions were associated
with a reduction in protein synthesis due to the activation of
protein kinase R (PKR)-like ER kinases (PERK) and phosphor-
ylation of eIF2, as a compensatory mechanism [36–38]. Thus, it
appears that protein expression is the net outcome of competing
signaling pathways working for enhancement vs. reduction in
protein translation. Therefore, like any other growth pathway, the
effect of the activation of the mTOR pathway on the outcome-
protein synthesis- will be dependent on the net balance between
the activation of competing pathways for upregulation and
downregulation of protein translation.
The mTORC1 activation may not yield net outcome in the
form of enhanced protein synthesis and cellular hypertrophy at all
stages of disease, depending on the stimulatory and inhibitory
factors mentioned above. Diabetic nephropathy is characterized
by renal hypertrophy in general, and glomerular hypertrophy in
particular [39]. However, renal hypertrophy occurred during the
first month following diabetes induction in streptozotocin-treated
rats because of enhanced cap-dependent protein synthesis through
the activation of mTORC1 [28,29]; however, in the latter time
periods, cap-dependent protein synthesis was down regulated in
response to an ongoing oxidative [40] and ER stresses [41,42];
these stresses inhibited protein synthesis, and thus tilted the
balance towards negative protein balance.
Recently, the role of mTOR pathway has been demonstrated in
the development of HIVAN proliferative phenotype in cystic
tubules of HIVAN mice [7]; in addition to tubular cell
proliferation, occurrence of apoptosis was also displayed in
microcysts. Thus, it appears that in HIVAN too, mitogenic vs.
apoptotic pathways dominate at different time points. However,
the time course effect of mTOR pathway on the expression of
different protein expression profile was not evaluated in those
studies. Therefore, it will be interesting to evaluate the time course
effect of HIV-1 infection on the expression of renal tissue protein
profile in HIVAN in future studies.
Besides inhibition of mTOR pathway, rapamycin has also been
reported to display anti-HIV properties (43–47]. Roy et al
demonstrated that rapamycin inhibited LTR-mediated transcrip-
tion of HIV [43]. Recently, Heredia et al demonstrated that
rapamycin down regulated CCR5 and caused accumulation of
anti-HIV b-chemokines [44]. Moreover, in vitro studies, rapamycin
enhanced the anti-HIV activity of HIV-entry inhibitors including
vivcriviroc, aplaviroc and enfuvirtide [44,45]. In addition,
rapamycin attenuated HIV infection in human peripheral blood
leukocyte reconstituted SCID mice [46]. Furthermore, in a recent
prospective trial, rapamycin (as a monotherapy) showed signifi-
cantly better control of HIV and hepatitis C virus replication in
HIV patients with liver transplant [47]. Thus, it appears that
rapamycin not only attenuates HIV replication but also inhibits its
entry target cells expressing CCR5.
A schema proposing potential mechanism by which mTORC1
promotes protein synthesis in tubular epithelial cells in HIVAN is
shown in Fig. 10. The HIV-induced mTORC1 activation
proceeds with the rapamycin-sensitive phosphorylation of 4EBP1
which by freeing eIF4E promotes the initiation phase of mRNA
translation. Activation of mTORC1 leads to the phosphorylation
of p70S6 kinase, which phosphorylates eIF4B on Ser
422 [21].
During the initiation phase of translation, eIF4A, a DEAD box
protein, functions as a helicase resolving the complexities in
50UTR which facilitates the scanning of the pre-initiation complex
for the AUG codon; eIF4B assists in this activity [9]. Additionally,
p70S6 kinase inhibits the activity of eEF2 kinase, a calcium
calmodulin–dependent kinase, by phosphorylating it on Thr
366
[48]; reduced activity of eEF2 kinase would contribute to increase
in the level of eEF2 dephosphorylated on Thr
56; this results in
activation of eEF2 [49]. These events stimulate the elongation
phase of mRNA translation. Thus, the activation of mTORC1
pathway contributes to the translation of mRNA by stimulating
the initiation as well as the elongation phases. By targeting
mTORC1, rapamycin inhibits the two critical pathways in mRNA
translation that together promote protein synthesis.
We conclude that HIV-1 infection of tubular cells induces
activation of the mTORC1 pathway leading to stimulation protein
synthesis and thus contributing to tubular cell hypertrophy.
Rapamycin inhibits tubular cell protein synthesis by inhibting
the activation of the mTORC1. The present study provides insight
into the molecular mechanisms involved in tubular cell hypertro-
phy in HIVAN.
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